Daily pharmacologic prophylaxis of episodic migraine

Techniques in Regional Anesthesia and Pain Management

Volumn 13, Issue 1, 2009, Pages 20-27

  Bamford, Cynthia C ^a   Tepper, Stewart J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Headache; Migraine; Preventive therapy; Prophylaxis; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; ATENOLOL; BOTULINUM TOXIN A; CYCLANDELATE; DESVENLAFAXINE; DILTIAZEM; DOXEPIN; DULOXETINE; FLUOXETINE; FLURBIPROFEN; GABAPENTIN; IMIPRAMINE; LISURIDE; METHYSERGIDE; METOPROLOL; NADOLOL; NORTRIPTYLINE; PETASITES HYBRIDUS EXTRACT; PROPRANOLOL; PROTRIPTYLINE; RIBOFLAVIN; TANACETUM PARTHENIUM EXTRACT; TIMOLOL; TOPIRAMATE; VALPROATE SEMISODIUM; VALPROIC ACID; VENLAFAXINE; VERAPAMIL;

ANTICHOLINERGIC EFFECT; ARTICLE; ASTHENIA; ASTHMA; ATRIOVENTRICULAR BLOCK; BODY WEIGHT; BRADYCARDIA; CARDIOTOXICITY; CHANNELOPATHY; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; COGNITIVE THERAPY; CONGESTIVE HEART FAILURE; CONSTIPATION; DEPRESSION; DIABETIC PATIENT; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DROWSINESS; DRUG CONTRAINDICATION; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG USE; EVIDENCE BASED MEDICINE; EXERCISE INTOLERANCE; FEEDBACK SYSTEM; HEART ARRHYTHMIA; HUMAN; HYPOTENSION; LOW DRUG DOSE; MIGRAINE; MORBIDITY; NERVE BLOCK; NERVE EXCITABILITY; NONHUMAN; ORTHOSTATIC HYPOTENSION; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; PHYSICAL DISABILITY; PRACTICE GUIDELINE; PROPHYLAXIS; RAYNAUD PHENOMENON; REGIONAL ANESTHESIA; RELAXATION TRAINING; SIDE EFFECT; SINGLE DRUG DOSE; SPREADING CORTICAL DEPRESSION; TREATMENT DURATION; TREATMENT FAILURE; VITAMIN SUPPLEMENTATION; XEROSTOMIA;

EID: 66949148244     PISSN: 1084208X     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.trap.2009.03.001     Document Type: Article

References (40)

1. International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 24 (2004) 1-60
2. Stewart W., Schecter A., and Rasmussen R.K. Migraine prevalence. A review of population-based studies. Neurology 44 suppl (1994) S17-S23
3. Hu X., Markson L., Lipton R., et al. Burden of migraine in the United States: Disability and economic costs. Arch Intern Med 159 (1999) 813-818
4. Leao A.A.P. Spreading depression of activity in the cerebral cortex. J Neurophysiol 7 (2003) 359-390
5. Gursoy-Ozdemir Y., Qiu J., Matsuoka M., et al. Cortical spreading depression activates and up-regulates MMP. J Clin Invest 113 (2004) 1447-1455
6. Cao Y., Aurora S.K., Nagesh V., et al. Functional MRI-BOLD of brainstem structures during visually triggered migraine. Neurology 59 (2002) 72-78
7. Woods R.P., Iacoboni M., and Mazziotta J.C. Brief report: Bilateral spreading cerebral hypoperfusion during spontaneous migraine headache. N Engl J Med 331 (1994) 1689-1692
8. Pietrobon D., and Streissing J. Neurobiology of migraine. Nature 4 (2003) 386-398
9. Raskin N., Hosobuchi Y., and Lamb S. Headache may arise from perturbation of the brain. Headache 27 (1987) 416-420
10. Weiller C., May A., Limroth V., et al. Brainstem activation in spontaneous human migraine attacks. Nat Med 1 (1995) 658-660
11. May A., and Goadsby P.J. The trigeminovascular system in humans: Pathophysiologic implications for primary headache syndromes of the neural influences on the cerebral circulation. J Cereb Blood Flow Metab (1999) 19
12. Goadsby P.J., Lipton R.B., and Ferrari M.D. Migraine-current understanding and treatment. N Engl J Med (2002) 346
13. Dimitriadou V., and Theoharides T.C. Ultrastructural evidence for neurogenically mediated changes in blood vessels in the rat dura mater and tongue following antidromic trigeminal stimulation. Neuroscience 48 (1992) 187-203
14. Burstein R., Collins B., Jakubowki M., et al. Defeating migraine pain with triptans: A race against the development of cutaneous allodynia. Ann Neurol 55 (2004) 19-26
15. Silberstein S.D., and Goadsby P.J. Migraine: Preventive treatment. Cephalalgia 22 (2002) 491-512
16. Bigal M.E., Serrano D., Buse D., et al. Acute migraine medications and evolution from episodic to chronic Migaine: A longitudinal population-based study. Headache 48 (2008) 1157-1168
17. Ayata C., Jin H., Kudo C., et al. Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol 59 (2006) 652-661
18. Heninger F.R., and Charney D.S. Mechanism of action of antidepressant treatments: Implications for the etiology and treatment of depressive disorders. In: Melzer H.Y. (Ed). Psychopharmacology: The Third Generation of Progress (1987), Raven, New York 535-544
19. Peroutka S.J. Developments in 5-Hydroxytriptamine receptor pharmacology. In: Mathew N.T. (Ed). Headache. Neurologic Clinics vol. 8 (1990), WB Saunders Company, Philadelphia, PA 829-839
20. Ablad B., and Dahlof C. Migraine and beta-blockade: Modulation of sympathetic neurotransmission. Cephalalgia 6 (1986) 7-13
21. Miljanich G., and Ramachandran J. Antagonists of neuronal calcium channels: Structure, function, and therapeutic implications. Annu Rev Pharmacol Toxicol 35 (1995) 707-734
22. Cutrer F., and Moskowitz M.A. Possible mechanisms of valproate and neurosteroids in a model of trigeminal pain. Headache 36 (1997) 579-585
23. Moskowitz M.A. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol Sci 13 (1992) 307-311
24. Mathew N.T., Rapoport A., Saper J., et al. Efficacy of gabapentin in migraine prophylaxis. Headache 41 (2001) 119-128
25. Shank R.P., Gardocki J.F., Streeter A.J., et al. An overview of the preclinical aspects of topiramate: Pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 41 suppl 1 (2000) S3-S9
26. Sheftell F., Rapoport A., Weeks R., et al. Montelukast in the prophylaxis of migraine: A potential role for leukotriene modifiers. Headache 40 (2000) 158-163
27. 2+ ratio. Headache 33 (1993) 135-138
28. Ramadan N., Halvorson H., Vande-Linde A., et al. Low brain magnesium in migraine. Headache 29 (1989) 590-593
29. Peikert A., WC, and Kohne-Volland R. Prophylaxis of migraine with oral magnesium: Results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia 16 (1996) 257-263
30. Bigal M.E., Bordini B.C., Tepper S.J., et al. Intravenous magnesium sulphate in the acute treatment of migraine without aura and migraine with aura. A randomized, double-blind, placebo-controlled study. Cephalalgia 22 (2002) 345-353
31. Tepper S.J., Bigal M., Rapoport A., et al. Alternative therapies: Evidence based evaluation in migraine. Headache Care 3 (2006) 57-64
32. Sandor P.S., DiClemente L., Coppola G., et al. A randomized controlled trial of coenzyme Q10 in migraine prophylaxis. Neurology 64 (2005) 713-715
33. Schoenen J., Jacquy J., and Lanaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. Neurology 50 (1998) 466-470
34. Fillipi G.M., Errico P., Santarelli R., et al. Botulinum A toxin effects on rat jaw muscle spindles. Acta Otolaryngol 113 (2004) 400-404
35. Aoki K.R. Evidence for antinociceptive activity of botulinum toxin type a in pain management. Headache 43 suppl 1 (2003) S9-S15
36. Durham P.L., Cady R., and Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type a: Implications for migraine therapy. Headache 44 (2004) 35-42
37. Ramadan N., Silberstein S.D., Freitag F.G., et al. Multispecialty consensus on diagnosis and treatment of headache: Pharmacological management for prevention of migraine Neurology, 2000. serial online at:. http://www.aan.com/professionals/practice/pdfs/g10090.pdf
38. Joffe H., Cohen L.S., Suppes T., et al. Valproate is associated with new-onset oligomenorrhea with hyperandrogenism in women with bipolar disorder. Biol Psychiatry 59 (2006) 1078-1086
39. Allegran. http://www.allergan.com Accessed September 21, 2008
40. Lipton R.B., Silberstein S.D., Saper J.R., et al. Why headache treatment fails. Neurology 60 (2003) 1064-1070